MRE-269-d7

• CAT Number: I042561
• CAS Number: 1265295-20-2
• Molecular Formula: C25H22D7N3O3
• Molecular Weight: 426.56
• Purity: ≥95%
• Synonyms: 2-[4-[(5,6-diphenylpyrazin-2-yl)-(1,1,1,2,3,3,3-heptadeuteriopropan-2-yl)amino]butoxy]acetic acid
• InChI: InChI=1S/C25H29N3O3/c1-19(2)28(15-9-10-16-31-18-23(29)30)22-17-26-24(20-11-5-3-6-12-20)25(27-22)21-13-7-4-8-14-21/h3-8,11-14,17,19H,9-10,15-16,18H2,1-2H3,(H,29,30)/i1D3,2D3,19D
• InChIKey: OJQMKCBWYCWFPU-HXAWLNHQSA-N
• SMILES: [2H]C([2H])([2H])C([2H])(C([2H])([2H])[2H])N(CCCCOCC(=O)O)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3

MRE-269-d7（Cat No.:I042561）is a deuterated version of MRE-269, a selective inhibitor of the mechanistic target of rapamycin (mTOR) pathway. The incorporation of deuterium (d7) enhances the compound’s metabolic stability, providing a more robust pharmacokinetic profile in research. MRE-269-d7 is used in studies to investigate mTOR signaling, which plays a crucial role in cell growth, metabolism, and survival. This inhibitor is explored for its potential in treating cancers, metabolic disorders, and conditions where mTOR dysregulation contributes to disease progression, offering valuable insights into therapeutic development.